Show results for
Refine by
Tumor Immune Suppliers Serving Norway
35 companies found
based inIllkirch-Graffenstaden, FRANCE
Transgene is a clinical-stage biotechnology company focused on designing and developing novel immunotherapeutics. Every day, we push the boundaries of innovation with our therapeutic vaccines and oncolytic viruses, to design better treatments for ...
TG4001 is an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 ...
based inBremen, GERMANY
OMNI Life Science provides cutting edge solutions for cell research. Focusing on people and innovations throughout, our mission is to promote research in Life Sciences with smart, reliable and user-friendly technology. We are highly specialized on ...
based inBerlin, GERMANY
JPT Peptide Technologies GmbH is a leading provider of custom peptides and innovative peptide-based services and products. We are a research and development partner for projects in immunotherapy and vaccine Development, immune monitoring, proteomics ...
PepSup is a highly standardized, peptide-based cell activation (cell stimulation) assay designed to produce short-term culture supernatants for analysis of cytokines or other mediators of interest. We create your PepSup Cell Activation Kit with your ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
based inCambridge, MASSACHUSETTS (USA)
Myeloid Therapeutics is a leader in the development of mRNA-based immunotherapies, focusing on harnessing and enhancing the natural capabilities of myeloid cells to combat cancer. The company's cutting-edge in vivo engineering platform is designed ...
Myeloid is focused on advancing its ATAK CAR monocytes, which are myeloid cells with innate immune receptor-inspired CARs to recognize and kill cancer. Additionally, Myeloid has streamlined manufacturing for its ATAK cell therapy candidates through ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Tulmimetostat is a second-generation EZH2 inhibitor that has been designed to achieve comprehensive target coverage through extended on-target residence time. EZH2 acts as an epigenetic writer and normally places one or more methyl groups on a ...
based inMarseille Cedex 9, FRANCE
Veracyte, formerly HalioDx, is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. Our ...
Designed to deliver critical information to guide chemotherapy decision-making, Immunoscore® can be used in Stage II localized colon cancer to help physicians identify patients who may be spared adjuvant chemotherapy, and in Stage III ...
based inWroclaw, POLAND
Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based ...
TNBC can be further categorized into three types: Type 1 (also known as the “cold” type) is characterized by a tumor with low infiltration of immune cells into the tumor ...
based inBedminster, NEW JERSEY (USA)
Jubilant Therapeutics Inc. is a clinical stage precision therapeutics company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. With an advanced discovery engine which ...
Strong scientific and clinical rationale for LSD1/HDAC6 inhibition in haematological and solid ...
based inSeattle, WASHINGTON (USA)
As the pioneer in the field of spatial biology, NanoString enables scientists across the globe to envision molecular interactions in three dimensions with three different systems, the nCounter Analysis System, the GeoMx Digital Spatial Profiler ...
The GeoMx Immune Pathways Panel is designed for targeted profiling of the tumor, tumor microenvironment, and tumor immune status. Profile up to 96 RNA targets with ...
based inChatham, NEW JERSEY (USA)
Tonix is a clinical-stage biopharmaceutical company focused on developing novel therapies and vaccines to prevent and treat central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. At Tonix, we are focused on ...
TFF2 is a small, secreted protein, encoded by the TFF2 gene in humans that is expressed in gastrointestinal mucosa where it functions to protect and repair mucosa. TFF2 is also expressed at low levels in splenic immune cells and is ...
based inBrea, CALIFORNIA (USA)
We are pleased to announce the exclusive commercialization and sale of KinesisDx product lines to Krishgen Biosystems, India for worldwide usage effective July 11, 2019. This is in line with our philosophy to partner with forward looking companies ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
Advances in the field of immuno-oncology have led to new and better treatment outcomes for a range of cancers, and particularly, blood cancers. However, even with the advent of checkpoint inhibitors as immunotherapies for solid ...
based inAmsterdam, NETHERLANDS
Founded in 1997, Kiadis Pharma is a fully integrated biopharmaceutical company committed to developing innovative, personalized, next-generation cell-based immunotherapies for patients with life threatening diseases. With headquarters in Amsterdam, ...
Ushering in the Future of NK-cell Therapy: Natural killer (NK) cells have long been known to play a significant role in the body’s innate immune response. They were first described in the 1970s, but only in the last 15 years ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
ACTallo® is a process developed by Immatics for the manufacture of allogeneic, off-the-shelf, TCR-engineered cellular therapies derived from healthy donors’ gamma delta T ...
based inHørsholm, DENMARK
We are an AI-immunology platform company decoding the human immune system to discover and develop novel immunotherapies for cancer and infectious diseases. We have developed our AI-immunology core technology to deeply understand the biological ...
PIONEER is our proprietary AI platform for the rapid discovery and design of patient-specific neoepitopes used to derive immuno-oncology therapies. It has been shown that neoepitopes, which arise from patient-specific tumor ...
based inAtlanta, GEORGIA (US) (USA)
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a ...
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane ...
based inNewark, DELAWARE (USA)
ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across ...
IL-15,Interleukin-15,IL15,Interleukin ...
based inBoston, MASSACHUSETTS (USA)
We harness the natural power of the lymph nodes to generate enhanced immune responses against tumors. Our science is defining the future of immunotherapy, with the goal of giving patients who are battling cancer their best possible outcome. We’re ...
Our lymph node-targeted mKRAS cancer vaccine; Our Amphiphile (AMP)-powered lead candidate, ELI-002, generates a robust immune response against mutant Kristen rat sarcoma (mKRAS), with the potential to offer patients a stronger fight ...
based inRedmond, WASHINGTON (USA)
SystImmune Inc. is a biopharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs). Our objective is to create biologics that ...